[Functional outcome in schizophrenia: a comparative cross-sectional study on first versus second generation...

Area of Science:

• Psychiatry
• Neuroscience
• Clinical Psychology

Background:

• Schizophrenia management often involves antipsychotic medication.
• First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are common treatment options.
• Comparing their impact on cognitive and functional outcomes is crucial for optimizing patient care.

Purpose of the Study:

• To compare executive functions, social functioning, and quality of life in stable schizophrenia outpatients treated with FGAs versus SGAs.
• To evaluate the differential effects of antipsychotic generations on key patient outcomes.

Main Methods:

• A cross-sectional study included 168 stable schizophrenia outpatients on FGAs or SGAs.
• Executive functions assessed using the Wisconsin Card Sorting Test (WCST).
• Global Assessment of Functioning (GAF) and Quality of Life Scale (QLS) evaluated functioning and quality of life.

Main Results:

• Patients on SGAs demonstrated significantly better performance on the WCST, with more completed categories and fewer perseverative errors.
• SGAs were associated with higher GAF scores, indicating better overall functioning.
• Patients receiving SGAs reported significantly higher scores on the QLS subscale for instrumental role.

Conclusions:

• Second-generation antipsychotics appear to offer superior outcomes in neurocognition and social functioning for stable schizophrenia patients.
• Treatment with SGAs may lead to enhanced working skills and overall quality of life.
• These findings support the consideration of SGAs for improving comprehensive outcomes in schizophrenia management.